Hesperidin

Hesperidin: A Comprehensive Reference Article

1. Identity: Chemical Classification, Botanical Source, and Nomenclature

Chemical Name and Classification

Hesperidin (3,5,7-trihydroxyflavanone 7-rhamnoglucoside; hesperetin-7-O-rutinoside) belongs to the flavanone subclass of flavonoids. Its molecular formula is C₂₈H₃₄O₁₅, and it is formally designated 3′,5,7-trihydroxy-4′-methoxy-flavanone-7-O-rutinoside — a flavanone glycoside with poor solubility in water and most organic solvents. Structurally, hesperidin is a glycoside having rutinose (α-L-rhamnopyranosyl-[1→6]-β-D-glucopyranose) linked to the OH-7 position of its aglycone, hesperetin [(3′,5,7-trihydroxy-4′-methoxy-flavanone), or (S)-5-hydroxy-2-(3-hydroxy-4-methoxy-phenyl)-2,3-dihydro-4H-chromen-4-one].

Hesperidin presents the typical flavonoid backbone structure of C6–C3–C6, consisting of two phenyl rings connected through a heterocyclic pyran ring. This glycosylated flavanone is more abundant in nature than its respective aglycone, hesperetin, which is considered mainly responsible for its bioactivity. Hesperidin consists of the aglycone hesperetin attached to a sugar (rutinose) molecule.

Etymology and Discovery

Its name is derived from the word "hesperidium," for the type of fruit produced by citrus trees. Hesperidin was first isolated in 1828 by French chemist M. Lebreton from the white inner layer of citrus peels (mesocarp, albedo). Through the 20th century, researchers mapped its structure and began investigating its bioactivity.

Botanical Sources

Hesperidin and its derivatives are characteristic compounds of citrus fruits (Rutaceae family) such as orange (Citrus sinensis), grapefruit (Citrus paradisi), tangerine (Citrus reticulata), lime (Citrus aurantifolia), and lemon (Citrus limon). Their content in citrus fruits depends on fruit variety, part of the fruit, climate, and degree of maturation.

Among citrus sources, hesperidin is the predominant flavonoid in citrus fruits, primarily in sweet orange — in young, immature oranges it accounts for up to 14% of dry matter. Representative concentrations in juice include sweet and red oranges (28.6 and 43.6 mg/100 mL of juice, respectively), tangerine (24.3 mg/100 mL of juice), clementine (39.9 mg/100 mL of juice), and lemon (20.5 mg/100 mL of juice). Apart from citrus, this flavonoid has also been identified in other plant species such as Mentha piperita L. (504.2 mg/L) and Stevia rebaudiana (493.4 mg/L).

Hesperidin is believed to play a role in plant defense. It is present at 700–2,500 ppm in the fruit of Citrus aurantium (bitter orange). Flavonoid-enriched tissues of citrus — such as peel, immature fruit, and flower — are consumed as culinary seasonings and tea ingredients in China for centuries.

Biosynthesis

The biosynthesis of hesperidin stems from the phenylpropanoid pathway, in which the natural amino acid L-phenylalanine undergoes deamination by phenylalanine ammonia lyase to afford (E)-cinnamate. The resulting monocarboxylate undergoes oxidation by cinnamate 4-hydroxylase to afford (E)-4-coumarate, which is transformed into (E)-4-coumaroyl-CoA by 4-coumarate-CoA ligase. That compound is subjected to the type III polyketide synthase naringenin chalcone synthase, undergoing successive condensation reactions and a ring-closing Claisen condensation to afford naringenin chalcone. The chalcone undergoes isomerization by chalcone isomerase to afford (2S)-naringenin, which is oxidized to (2S)-eriodictyol by flavonoid 3′-hydroxylase. After O-methylation by caffeoyl-CoA O-methyltransferase, the hesperetin product undergoes glycosylation by flavanone 7-O-glucosyltransferase to afford hesperetin-7-O-β-D-glucoside.

2. Common Forms, Preparations, and Commercial Products

Raw hesperidin has poor water solubility, which limits both oral absorption and topical application. This fundamental limitation has driven the development of several modified forms for supplementation and pharmaceutical use.

• Standard hesperidin: Most studies using hesperidin tend to use about 500 mg of supplemental hesperidin, employing the standard form if taken as a daily preventative.
• Glucosyl hesperidin (G-hesperidin): A synthetic variant of hesperidin in which the aglycone (hesperetin) is unchanged but the diglycoside group has been modified into a triglycoside. This variant has increased water solubility approximately 10,000-fold relative to hesperidin. In the body, it is metabolized by intestinal α-glucosidases, releasing hesperidin (glycone), which in turn releases free hesperetin.
• Hesperidin methyl chalcone (HMC): A derivative that may be used to supply hesperidin in formulations and has been demonstrated to have high bioavailability. HMC is a methylated derivative of hesperidin found in several citrus fruits, taking the form of a pale yellow, slightly bitter, water-soluble powder.
• Micronized purified flavonoid fraction (MPFF): MPFF consists of micronized diosmin (90%) and other active flavonoids including hesperidin, diosmetin, linarin, and isorhoifolin (10% combined), and has shown clinical efficacy in the treatment of chronic venous disease and hemorrhoidal disease. Diosmin and several other components of MPFF are synthesized from hesperidin, which is extracted from Citrus aurantium var. amara, a type of small, bitter, immature orange.

Other synonyms and commercial designations in use include: alpha-glucosylhesperidin, bioflavonoids, citrus flavonoids, G-hesperidin, hesperidin-7-O-rutinoside, hesperidin methyl chalcone (HMC), micronized purified flavonoid fraction, MPFF, and vitamin P, among others.

3. Traditional and Historical Use

Traditional Chinese Medicine

Traditional herbalists have utilized the peels of citrus fruits for thousands of years in the treatment of various diseases and disorders. In Asia, orange zest, lemon zest, and dried orange peel are common ingredients in cooking for medicinal healing and treatment of digestive disorders. Traditional Chinese medicine (TCM) doctors utilize mature mandarin orange peel, known as Chen Pi or Ju Pi, to improve digestion, relieve gas and bloating, and resolve phlegm. In traditional medicine, the peel acts primarily on the digestive and respiratory systems, alleviating fullness and distention, and treating loss of appetite, vomiting, and diarrhea. Immature mandarin orange peel — or Qing Pi — may act on the liver and stomach to promote digestion and relieve food stagnation.

Hesperidin is widely known in traditional Chinese medicine alongside naringenin as Chimpi, wherein the dried peels of citrus have been used medicinally. Flavonoid-enriched tissues of citrus such as peel, immature fruit, and flower are consumed as culinary seasonings and tea ingredients in China for centuries. An HPLC quantitative study on five citrus flavonoids — naringin, hesperidin, neohesperidin, sinensetin, and nobiletin — on a wide range of Chinese citrus fruits and several TCM food ingredients in East China revealed a great diversity in flavonoid composition.

European Folk Medicine

In European folk medicine, citrus peel infusions were historically used to treat poor digestion, sluggish circulation, and colds, often as part of broader herbal preparations. By the mid-20th century, hesperidin had become a staple in vascular-health studies, mostly in Europe.

It is important to note that none of these traditional usages referred specifically to hesperidin as an isolated compound. The compound itself was not isolated until 1828 and was not characterized structurally until decades later. Traditional practitioners worked with whole citrus peels and decoctions, in which hesperidin was one of many active constituents.

4. Key Constituents, Metabolites, and Mechanisms of Action

Primary Active Form: Hesperetin

The actual active form derived from hesperidin is its aglycone hesperetin (5,7,3′-trihydroxy-4′-methoxyflavanone); thus hesperidin acts as a hesperetin prodrug, supplying the body with hesperetin. After ingestion, hesperidin is hydrolyzed by gut microflora into the aglycone form (hesperetin) and then conjugated mainly into glucuronides.

The gut microbiome plays a meaningful role in how much hesperidin actually reaches target tissues, which partly explains why bioavailability is variable between individuals. Due to its low water solubility, weak intestinal absorption, disposition via phase II enzymes, and efflux by enterocytes, hesperidin's oral bioavailability is less than 20%, and it is quickly altered by environmental conditions such as temperature, pH, and light.

Antioxidant Mechanisms

Hesperidin (Hsd) and its aglycone, hesperetin (Hst), are two flavonoids from citrus species that have numerous biological properties, particularly antioxidant and anti-inflammatory. New findings show that the antioxidant activity of Hsd/Hst is not only limited to radical scavenging activity but also augments antioxidant cellular defenses via the ERK/Nrf2 signaling pathway. Various in vitro and in vivo studies have evaluated Hsd, its metabolites, or its synthetic derivatives at reducing inflammatory targets including NF-κB, iNOS, and COX-2, and the markers of chronic inflammation.

Hesperidin, as a bioflavonoid, provides antioxidant benefits via enhanced activity and production of cellular antioxidant enzymes such as superoxide dismutase (SOD), heme oxygenase-1 (HO-1), catalase, and others, and elevation of the predominant cellular antioxidant, glutathione.

The mechanism of neuroprotection against heavy metal toxicity is mediated via the Nrf2 (nuclear factor erythroid 2 factor) pathway, which significantly improves the extent of antioxidants that reduce lipid peroxidation and metal-induced oxidative stress.

Anti-Inflammatory Mechanisms

According to current studies, hesperidin can inhibit transcription factors or regulatory enzymes essential for controlling inflammation-linked mediators, including nuclear factor-kappa B (NF-κB), inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2). It also improves cellular antioxidant defenses by activating the ERK/Nrf2 signaling pathway.

Hesperidin and hesperetin inhibit the Txnip/NLRP3, MAPK, and NF-κB inflammatory pathways; upregulate HO-1 expression; inhibit the activation of Txnip and its binding to NLRP3; and impede the binding of NLRP3 to downstream caspase-1 and ASC, thereby inhibiting inflammatory body activation and downregulating IL-1β levels.

The mechanism behind hesperidin's anti-inflammatory capacity is its ability to halt the NF-κB pathway. Suppression of NF-κB results in decreased production of pro-inflammatory cytokines.

Vascular and Endothelial Effects

In the context of vascular health, diosmin is mainly responsible for improving venous contractility and reducing inflammatory remodeling, whereas hesperidin primarily protects the endothelium and alleviates oxidative stress.

Antiproliferative and Cancer-Related Mechanisms (Preclinical)

In cancer models, hesperidin exerts antiproliferative activity by inhibiting cell viability, colony formation, and glycolytic enzyme expression; displays chemopreventive properties by reducing aberrant crypt foci and modulating phase I/II detoxifying enzymes; shows anti-inflammatory effects through downregulation of NF-κB, COX-2, iNOS, and pro-inflammatory cytokines; and enhances antioxidant defense by scavenging ROS and activating the ERK/Nrf2/HO-1 signaling pathway.

5. Scientific Evidence by Area of Use

5.1 Cardiovascular Risk Factors: Lipids and Blood Pressure

This is the most clinically studied area for hesperidin supplementation. Multiple systematic reviews and meta-analyses of randomized controlled trials (RCTs) exist, although their conclusions differ, reflecting variability in study populations, doses, and forms of hesperidin used.

Evidence supporting lipid reduction: A systematic review and meta-analysis searched online databases including PubMed and Google Scholar up to April 2023, including randomized controlled studies on hesperidin against various cardiovascular and metabolic disorders in healthy or diseased individuals compared to placebo or control. Based on inclusion and exclusion criteria, nine clinical studies involving 2,414 subjects were included. The meta-analysis revealed that hesperidin significantly reduced LDL (IV: −0.55 [−0.94 to −0.16], 95% CI, p = 0.005, I² = 70%), total cholesterol (TC) (IV: −0.61 [−0.82 to −0.41], 95% CI, p < 0.00001, I² = 69%), and triglycerides (TG) (IV: −0.21 [−0.40 to −0.02], 95% CI, p = 0.03, I² = 12%).

A 2023 comprehensive search conducted up to August 2022 in Scopus, PubMed, Embase, Cochrane Library, and ISI Web of Science reviewed all RCTs. The results showed that hesperidin supplementation had a significant effect on reducing serum triglyceride (TG), total cholesterol (TC), low-density lipoprotein (LDL), tumor necrosis factor-alpha (TNF-α), and systolic blood pressure (SBP), whereas body weight was increased.

A further meta-analysis including 12 trials with 589 participants found significant effects of hesperidin on LDL cholesterol (WMD: −0.22 mmol/L; 95% CI: −0.33, −0.11 mmol/L), total cholesterol (WMD: −0.20 mmol/L; 95% CI: −0.31, −0.08 mmol/L), fasting blood glucose (WMD: −0.15 mg/dL), intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and C-reactive protein (CRP), whereas no effects were found for other cardiovascular risk factors. The authors concluded that hesperidin might be advantageous in improving numerous cardiovascular risk factors, including blood lipid concentrations, blood glucose control, and management of inflammatory indicators.

Conflicting evidence — earlier meta-analysis: An earlier study aimed to evaluate the efficacy of hesperidin supplementation on lipid profile and blood pressure through a systematic review and meta-analysis of RCTs, searching PubMed, Web of Science, Scopus, and Google Scholar up to May 2018. Ten RCTs (577 participants) were included. That meta-analysis revealed that hesperidin supplementation had no statistically significant effect on serum total cholesterol (WMD = −1.04 mg/dL; 95% CI: −5.65, 3.57), LDL (WMD = −1.96 mg/dL; 95% CI: −7.56, 3.64), HDL, or triglycerides, with no significant between-study heterogeneity.

The discrepancy between the earlier (2018) null-finding meta-analysis and more recent meta-analyses (2023–2024) likely reflects the inclusion of newer and larger RCTs. The high heterogeneity (I² up to 70%) observed in the more recent meta-analyses also indicates that results across trials are not fully consistent. Overall, hesperidin exhibits promising potential in reducing risk factors associated with cardiovascular disease, such as triglycerides and total cholesterol, and it appears to have some anti-inflammatory properties. However, further clinical studies are required to fully understand its range of effects.

5.2 Chronic Venous Insufficiency and Hemorrhoidal Disease

Hesperidin's most extensively documented clinical use is within the context of the pharmaceutical preparation MPFF (micronized purified flavonoid fraction), in which it is a minority but synergistic component alongside diosmin.

Flavonoids are oral venoactive drugs frequently prescribed to relieve symptoms of chronic venous disorders (CVD). Among venoactive drugs, diosmin is a naturally occurring flavonoid glycoside; it can also be obtained after conversion of hesperidin extracted from citrus rinds. MPFF is a preparation that contains mainly diosmin and a small fraction of hesperidin. A state-of-the-art literature review collected and analyzed well-conducted randomized clinical studies comparing non-micronized diosmin 600 mg/day and MPFF 1,000 mg/day. These clinical studies showed a significant decrease of CVD symptom intensity (up to approximately 50%) and global patient satisfaction after one-to-six months of treatment with diosmin or MPFF, without statistical differences between treatments.

Previous non-systematic reviews have found evidence for the efficacy of MPFF not only in reducing pain, bleeding, anal discharge, and prolapse in acute hemorrhoidal disease, but also in preventing relapse and reducing the duration and severity of acute attacks in chronic hemorrhoidal disease. A 2006 meta-analysis of 14 studies investigating flavonoid treatment (MPFF, diosmin, or rutosides) for hemorrhoids reported that flavonoids reduced the risk of not improving globally by 58%, with apparent reductions in the risks of bleeding, pain, itching, and recurrences.

It should be noted that in both venous insufficiency and hemorrhoidal contexts, hesperidin is always studied as part of a combination product (MPFF), not as a standalone intervention. Its individual contribution cannot be cleanly separated from that of diosmin and other components.

5.3 Glycemic Control and Diabetes

The evidence for hesperidin's effect on blood glucose markers in humans is mixed and, on balance, does not yet reach a positive consensus.

A systematic review and meta-analysis revealed that hesperidin supplementation does not significantly affect different markers of blood glucose control including fasting blood glucose, plasma insulin, glycated hemoglobin A1c, homeostasis model assessment for insulin resistance (HOMA-IR), and quantitative insulin sensitivity check index (QUICKI) in human adults.

Overall findings from one 2023 systematic review suggest that hesperidin supplementation may not have a significant effect on blood glucose markers based on the available evidence. An earlier systematic review in 2019 evaluated the effects of hesperidin consumption on cardiovascular risk biomarkers in animal studies and human RCTs. Although hesperidin had beneficial effects in reducing glucose levels in animal models, no consensus was achieved considering hesperidin's effect on cardiovascular risk biomarkers in humans. Glucose levels and insulin were evaluated in human studies, but no significant changes were found.

By contrast, the 2024 meta-analysis (12 trials, 589 participants) did identify a significant effect on fasting blood glucose (WMD: −0.15 mg/dL; 95% CI: −0.29, −0.02 mg/dL) and quantitative insulin-sensitivity check index. Taken together, results across multiple meta-analyses are inconsistent, and the clinical significance of any effect on blood glucose remains uncertain.

At the preclinical level, hesperidin shows promise as a biomolecule for treating diabetic neuropathy, primarily through activation of nuclear factor erythroid 2-related factor 2 (Nrf-2), as an antioxidant-response element signaling, leading to neuroprotective effects. However, these findings are from cell and animal studies and have not been confirmed in adequately powered human trials.

5.4 Inflammation and Inflammatory Markers

A 2023 systematic review and dose-response meta-analysis showed that hesperidin supplementation had a significant effect on reducing tumor necrosis factor-alpha (TNF-α). The 2024 meta-analysis corroborated this, demonstrating significant reductions in ICAM-1 (WMD: −13.60 ng/mL; 95% CI: −23.72, −3.48 ng/mL), VCAM-1 (WMD: −15.60 ng/mL; 95% CI: −30.13, −1.06 ng/mL), and CRP (WMD: −0.56 mg/L; 95% CI: −1.11, −0.01 mg/L).

Mechanistically, most anti-inflammatory data derive from in vitro and animal models. Hesperidin has exhibited significant antioxidant, anti-inflammatory, anticancer, and hepatoprotective activities as well as anti-diabetes, antiadipogenic, antihypertensive, and antimicrobial activities confirmed in in vitro and in vivo studies. However, there is a lack of clinical data on the biological benefits of hesperidin. It is necessary to clinically investigate more on this phytochemical mechanism in different diseases, especially cancer and neurodegenerative diseases.

5.5 Neuroprotection and Cognitive Function

Evidence for hesperidin's neuroprotective effects is primarily preclinical. Hesperidin is reported for neuroprotective behavior via various mechanisms including heavy metal chelation and enhanced enzymatic activity of glutathione-S-transferase, catalase, superoxide dismutase, and glutathione peroxidase. An increase in these enzymes can effectively manage reactive oxygen species (ROS) and lipid peroxidation, which ensures neuronal health.

Hesperidin and hesperetin demonstrate potential as novel therapeutic agents for the treatment of Alzheimer's disease-like neurodegenerative disorders owing to their anti-inflammatory and antioxidant properties. However, these findings are based on preclinical models. The modulation of the gut microbiome by flavanones has been associated with improvements in cognitive performance and a reduced risk of neurodegenerative disorders. Despite promising findings, further research is needed to determine optimal dosages, strategies to enhance bioavailability, and long-term safety profiles.

Laboratory and animal data support antioxidant, anti-inflammatory, and neuroprotective mechanisms, and some small human studies suggest modest benefits for inflammatory markers, metabolic syndrome features, and cognitive outcomes, yet these pathways are plausible rather than proven at scale; reviewers repeatedly call for larger, well-controlled trials using hesperidin alone to isolate effects from combination products.

5.6 Respiratory and Pulmonary Health

Research into hesperidin's effects on respiratory disease is primarily preclinical. Hesperidin downregulates the TGF-β1/Smad3/AMPK and NF-κB pathways, resulting in improved regulation of oxido-inflammatory markers (such as Nrf2 and HO-1) and proinflammatory markers (such as TNF-α, IL-1β, IL-6) and reduced collagen deposition during pulmonary fibrosis. In a mouse model of bleomycin-induced pulmonary fibrosis, hesperidin downregulated the IL-6/STAT3 pathway, resulting in upregulation of P53, p21, and p16 (myofibroblast markers), and ameliorated pulmonary fibrosis. The anti-inflammatory, antioxidant, and anti-cancer properties of hesperidin and hesperetin suggest their potential clinical application in the treatment of respiratory diseases, including pulmonary fibrosis. These data derive entirely from animal models; controlled human trials in this area are lacking.

5.7 Antiviral Potential

Interest in hesperidin's antiviral properties was substantially elevated during the COVID-19 pandemic. Several computational methods, mostly docking studies, showed that hesperidin may bind to multiple regions of SARS-CoV-2 (spike protein, ACE2, and proteases). Hesperidin has a low binding energy with both the SARS-CoV-2 spike protein responsible for internalization, and also with the PLpro and Mpro responsible for viral replication. This suggests that these flavonoids could act as prophylactic agents by blocking several mechanisms of viral infection and replication, helping the host cell to resist viral attack. These are, however, computational and in vitro findings only; clinical evidence in humans for antiviral efficacy is not established.

5.8 Bone Health

Hesperetin and its metabolites have been reported to have several biological activities, including influencing bone strength and osteoblast differentiation. This evidence is preclinical; no robust human RCTs specifically on hesperidin and bone outcomes have been identified in the literature reviewed.

6. Body Systems and Health Areas Associated with Hesperidin

• Cardiovascular system: Hesperidin exhibits promising potential in reducing cardiovascular disease risk factors, such as triglycerides and total cholesterol. Vascular endothelial protection and anti-inflammatory effects on adhesion molecules (ICAM-1, VCAM-1) and CRP have also been documented in clinical meta-analyses.
• Venous and lymphatic system: Hesperidin is given as a supplement, often alongside diosmin, to treat patients with circulatory problems such as haemorrhoids, leg sores, and swelling in the legs due to venous insufficiency.
• Immune and inflammatory pathways: Suppression of NF-κB, COX-2, iNOS, and pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) is documented across numerous in vitro and animal studies, with some clinical corroboration in meta-analyses for TNF-α and CRP.
• Nervous system: Neuroprotective effects, particularly via Nrf2/ARE and ERK/JNK pathways, are documented in preclinical studies; human evidence is limited.
• Metabolic and endocrine system: Evidence for effects on fasting blood glucose and insulin sensitivity in humans is mixed and not conclusive across all meta-analyses.
• Respiratory system: Preclinical evidence supports anti-inflammatory and antifibrotic effects in lung tissue; no clinical human trials confirmed.
• Gastrointestinal system: Traditional use for digestive symptoms; some modern evidence through MPFF in hemorrhoidal disease management.

7. Dosage Forms and Dosages Reported in Studies

Most studies tend to use 500 mg or more of supplemental hesperidin, and use the standard form of hesperidin if taking it as a daily preventative.

For the prevention of muscle soreness associated with delayed onset muscle soreness (DOMS), a daily dosage of 500 mg of hesperidin methyl chalcone (HMC) for 3 days prior to intensive anaerobic exercise has shown positive outcomes in preliminary studies.

Short-term use — commonly up to 600 mg daily in trials — is generally considered possibly safe, with side effects limited to mild gastrointestinal complaints, headache, or skin reactions in some reports.

Hesperidin is generally tolerated short-term (commonly studied up to six months at doses around 500–600 mg).

In the MPFF context for chronic venous disorders, studies have compared diosmin 600 mg/day and MPFF 1,000 mg/day (the latter containing approximately 100 mg of hesperidin and related flavonoids).

For arthritis-related applications, beverages containing 3 grams of a hesperidin derivative have been used every morning for 12 weeks in some trial protocols.

Hesperidin is available in tablet, capsule, and beverage forms; the standard oral form is a tablet or capsule. A viable strategy for improving hesperidin oral bioavailability is the development of nanoscale drug carriers, which remain largely investigational.

8. Safety Considerations and Drug Interactions

General Tolerability

Hesperidin is relatively safe and well tolerated overall, but there is a general lack of clinical research examining potential side effects and drug interactions. Research suggests that hesperidin is generally well tolerated; however, thorough safety analyses still need to be done, and clinical evidence is lacking.

Side effects were not found due to hesperidin supplementation in most studies reviewed in at least one recent meta-analysis. While hesperidin is generally well-tolerated, some individuals may experience side effects including nausea, headache, and gastrointestinal discomfort.

Drug Interactions

Hesperidin is not considered safe for patients already taking anticoagulants, calcium channel blockers, or suffering from hypertension, because it acts as a blood thinner.

Hesperidin can alter drug transporters and may increase absorption or effects of drugs such as verapamil and other substrates, and it is not recommended for people on anticoagulants or before surgery without medical advice.

Individuals with low blood pressure should be careful, as hesperidin can further lower blood pressure, potentially leading to symptoms like dizziness or fainting.

Pregnancy and Lactation

Hesperidin is likely safe during pregnancy. While likely also safe during lactation, caution is advised due to a lack of evidence.

Duration of Use and Long-term Safety

Hesperidin is considered safe for use up to six months and does not cause serious side effects other than mild gastrointestinal upset. The duration of treatment using hesperidin depends on the condition treated.

Product Quality and Regulatory Status

According to the 2026 WADA List of Prohibited Substances, hesperidin is not prohibited.

Overall Evidence Summary

The balance of evidence positions hesperidin as a biologically active citrus flavonoid with plausible vascular and anti-inflammatory benefits and acceptable short-term tolerability, but key unanswered questions remain about optimal dosing, bioavailability solutions, long-term safety, clinically meaningful outcomes (heart attack, stroke, dementia prevention), and which effects — if any — translate into routine medical use rather than adjunctive or symptomatic therapy.

References

• Hesperidin: A Review on Extraction Methods, Stability and Biological Activities — PMC (2022)
• Effect of hesperidin on blood pressure and lipid profile: A systematic review and meta-analysis of randomized controlled trials — PubMed (2024)
• The effects of hesperidin supplementation on cardiovascular risk factors in adults: a systematic review and dose–response meta-analysis — Frontiers in Nutrition (2023)
• Effects of Citrus Flavanone Hesperidin Extracts or Purified Hesperidin Consumption on Risk Factors for Cardiovascular Disease: Evidence From an Updated Meta-analysis of Randomized Controlled Trials — PubMed (2024)
• Hesperidin, a major flavonoid in orange juice, might not affect lipid profile and blood pressure: A systematic review and meta-analysis — PubMed (2019)
• Hesperidin supplementation has no effect on blood glucose control: A systematic review and meta-analysis of randomized controlled clinical trials — PMC (2020)
• Promising influences of hesperidin and hesperetin against diabetes and its complications: a systematic review of molecular, cellular, and metabolic effects — PMC (2024)
• Antioxidant and anti-inflammatory properties of the citrus flavonoids hesperidin and hesperetin: an updated review of their molecular mechanisms and experimental models — PubMed (2015)
• Is There a Difference in the Clinical Efficacy of Diosmin and Micronized Purified Flavonoid Fraction for the Treatment of Chronic Venous Disorders? Review of Available Evidence — PMC (2021)
• Micronized Purified Flavonoid Fraction in Hemorrhoid Disease: A Systematic Review and Meta-Analysis — PMC (2020)
• Hesperidin — ScienceDirect Topics Overview
• Recent understanding of the mechanisms of the biological activities of hesperidin and hesperetin and their therapeutic effects on diseases — ScienceDirect (2024)
• Targeting colorectal cancer with hesperidin and hesperetin: a comprehensive review — Frontiers in Nutrition (2025)
• Hesperidin: a flavanone with multifaceted applications in the food, animal feed, and environmental fields — Phytochemistry Reviews, Springer Nature (2024)
• Pharmacological Significance of Hesperidin and Hesperetin as Promising Antiviral Compounds Against COVID-19 — Natural Product Communications, SAGE (2021)
• Hesperidin as a Neuroprotective Agent: A Review of Animal and Clinical Evidence — Molecules (2019)
• Current Update on Role of Hesperidin in Inflammatory Lung Diseases — PMC (2023)
• Hesperidin benefits, dosage, and side effects — Examine.com
• Hesperidin — Wikipedia
• The effects of hesperidin supplementation on cardiovascular risk factors in adults: a systematic review and dose–response meta-analysis — PMC (2023)